These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Acellular Spinal Cord Scaffold Implantation Promotes Vascular Remodeling with Sustained Delivery of VEGF in a Rat Spinal Cord Hemisection Model.
    Author: Xu ZX, Zhang LQ, Wang CS, Chen RS, Li GS, Guo Y, Xu WH.
    Journal: Curr Neurovasc Res; 2017; 14(3):274-289. PubMed ID: 28721809.
    Abstract:
    BACKGROUND: Promoting angiogenesis provides a possible therapeutic approach in treating spinal cord injury (SCI). Vascular endothelial growth factor (VEGF) is a pro-angiogenic substance that is involved in endothelial cell (EC) proliferation, migration, and survival. Exogenous administration of VEGF to the lesion epicenter of the spinal cord has been recently revealed as a potential method for promoting the blood vessel sprouting. METHODS: Spinal cord hemisection in a rat model was established and angiogenesis was studied through implant of an acellular spinal cord scaffold (ASCS) with sustained delivery of VEGF<sub>165</sub>. The poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating VEGF<sub>165</sub> were fabricated on basis of an emulsion and solvent evaporation method and conjugated to ASCS by a Genipin (GP) crosslinking technology. The resultant scaffolds were marked as V-ASCS. VEGF<sub>165</sub> entrapment efficiency (EE) and released kinetics were determined by an ultraviolet absorption measurement. Angiogenesis and vascular remodeling were observed via a high-resolution micro-CT and analyzed quantitatively by vascular morphometric parameters. Spinal cord histology and Basso, Beattie, and Bresnahan (BBB) locomotor rating scale were further studied. RESULTS: VEGF<sub>165</sub> was entrapped with high efficiency (90.8±3.1) %. In vitro VEGF<sub>165</sub> release kinetics study showed an initial burst of 1.966 μg mg NPs-1 and 1.045μg mg V-ASCS-1 respectively in the first 24 hours. In the phase of sustained release, approximately 0.040μg mg NPs-1 and 0.022μg mg V-ASCS-1 per day was on-going until 720h. In the rat spinal cord hemisection model, implant of V-ASCS at the injured site showed a promotion of angiogenesis and vascular remodeling following SCI. A better outcome can be confirmed histologically. However, functional improvement is limited in the animal model. CONCLUSION: The results indicate that progress of vascular reconstruction is accelerated in the V-ASCS implanted SCI rats.
    [Abstract] [Full Text] [Related] [New Search]